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In vertebrates ecto-50-nucleotidase (e5NT) catalyzes
the hydrolysis of extracellular AMP to adenosine and
represents the major control point for extracellular
adenosine levels. Due to its pivotal role for activation
of P1 adenosine receptors, e5NT has emerged as an
appealing drug target for treatment of inflammation,
chronic pain, hypoxia, and cancer. Crystal structures
of the dimeric human e5NT reveal an extensive 114
conformational switch between the open and closed
forms of the enzyme. The dimerization interface is
formed by the C-terminal domains and exhibits
interchain motions of up to 13. Complex structures
with adenosine and AMPCP indicate that structural
control of the domain movement determines the
selectivity for monophosphate nucleotides. Binding
modes of nucleotide-derived and flavonoid-based
compounds complexed to the C-terminal domain in
the open form reveal an additional binding pocket
of 210 A˚3 that might be explored to design more
potent inhibitors.
INTRODUCTION
Extracellular ATP, ADP, and adenosine are the main signaling
molecules involved in extracellular purinergic pathways. The
receptors include the adenosine-activated P1 receptors and
the ADP/ATP-activated P2X and P2Y receptors (Krissinel,
2011). Purinergic signaling is regulated by a family of cell
surface-located ecto-nucleotidases including the nucleoside
triphosphate diphosphohydrolases (NTPDases) and the ecto-
50-nucleotidase (e5NT, also known as CD73), which function as
part of an enzyme cascade to sequentially hydrolyze nucleotides
to their respective nucleosides and free phosphate (Zimmer-
mann, 1992; Zebisch and Stra¨ter, 2008; Yegutkin, 2008; Zebisch
et al., 2012; Zimmermann et al., 2012).
E5NT (EC 3.1.3.5) catalyzes the hydrolysis of AMP to adeno-
sine, and plays a crucial role in switching on adenosine signalingStructure 20, 2161–21via the P1 receptors (Zimmermann, 1992; Braun et al., 1995;
Colgan et al., 2006; Stra¨ter, 2006; Zimmermann et al., 2012).
With such an important regulatory role, human e5NT has
become an appealing drug target with potential applications in
the treatment of inflammation (Ohtsuka et al., 2010), chronic
pain (Sowa et al., 2010), and hypoxia (Thompson et al., 2004;
Li et al., 2006).
Furthermore, recent years have yielded a wealth of data impli-
cating CD73 enzymatic activity in promotion and metastasis of
cancer (Stagg and Smyth, 2010; Salmi and Jalkanen, 2012;
Stagg, 2012; Zhang, 2012). It is now evident that the hydrolytic
cascade from extracellular ATP to adenosine is one of the
most important immunosuppressive regulatory pathways in the
tumor microenvironment. Accordingly, e5NT, which is overex-
pressed in amultitude of cancer cell types, impairs adaptive anti-
tumor immune responses, and enhances tumor growth and
metastasis (Niemela¨ et al., 2004; Sadej et al., 2006; Braganhol
et al., 2007; Zhang, 2010, 2012). Decreasing e5NT activity with
monoclonal antibodies, siRNA, and small molecule inhibitors
including AMPCP (adenosine [(a,b)-methylene] diphosphate)
attenuates the growth and metastasis of tumors (Zhi et al.,
2007, 2010; Zhou et al., 2007; Stagg et al., 2010; Stagg and
Smyth, 2010). Tumor growth is also impaired in CD73-deficient
mice (Wang et al., 2011; Stagg et al., 2011, 2012; Yegutkin
et al., 2011) and it has been firmly established that these effects
are largely mediated by diminished adenosine production in
these mice (Jin et al., 2010; Stagg et al., 2011; Yegutkin et al.,
2011). These results suggest that eukaryotic e5NT plays an
important role in human health and disease, and targeting
tumor-derived e5NT may constitute an effective adjuvant, alone
or in combination with other therapeutic strategies, to fight tumor
progression (Jin et al., 2010; Stagg and Smyth, 2010; Yegutkin
et al., 2011; Stagg, 2012).
To date, there are no structures available for the eukaryotic
e5NT enzyme, thereby restricting the use of structure-based
drug design in developing small molecule inhibitors for human
e5NT. On the basis of primary sequence similarity, eukaryotic
e5NT is related to the bacterial 5NT enzymes and belongs to
a large superfamily of distantly related metallo-phosphoes-
terases comprising protein phosphatases, nucleotidases, and
nucleases (Koonin, 1994; Kno¨fel and Stra¨ter, 1999). Structures73, December 5, 2012 ª2012 Elsevier Ltd All rights reserved 2161
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Crystal Structure of Human Ecto-50-Nucleotidaseof several bacterial 5NT enzymes show that the enzyme consists
of two domains and exists in both open and closed conforma-
tions (Protein data bank [PDB] codes: 3ZU0 [Garavaglia et al.,
2012]; 1USH, 2USH, 1HO5, 1HP1, 1HPU, 1OI8, 1OID, and
1OIE [Kno¨fel and Stra¨ter, 1999, 2001a, 2001b; Schultz-Heien-
brok et al., 2004, 2005]; and 3IVD, 3IVE, and 2Z1A). Studies on
Escherichia coli 5NT have demonstrated that a domain motion
of 96 is necessary for enzyme catalysis, most likely to enable
substrate binding and product release from the open form (Kno¨-
fel and Stra¨ter, 2001a; Schultz-Heienbrok et al., 2004, 2005). A
structure is also available for Candida albicans 5NT (PDB code:
3C9F). Sequence comparisons show, however, that this enzyme
belongs to a subfamily of 5NTs that is only distantly related to the
bacterial and vertebrate homologs. Interestingly, the eukaryotic
e5NT enzymes display various structural and functional differ-
ences to their bacterial 5NT counterparts that cannot be under-
stood from studies on bacterial 5NT alone. Unlike themonomeric
bacterial 5NT enzymes that hydrolyze AMP, ADP, and also ATP
for purine salvage, the eukaryotic e5NT enzymes are dimeric and
specifically hydrolyze extracellular AMP and other nucleotide
monophosphates (Zimmermann, 1992). Interestingly, ADP and
ATP are competitive inhibitors of the eukaryotic e5NT enzymes,
with the most well characterized e5NT inhibitor being the ADP
analog AMPCP (Grondal and Zimmermann, 1987; Garcı´a-Ayllo´n
et al., 2001). E5NT is structurally not related to cytosolic 50-nucle-
otidases (Wallde´n et al., 2007).
Recent studies investigating eukaryotic e5NT inhibition have
identified a wide range of potent anthraquinone derivatives
with submicromolar inhibition constants (Baqi et al., 2010). A
virtual screening approach based on a homology model of
e5NT yielded inhibitors with a drug-like sulfonamide structure
(Ripphausen et al., 2012). Furthermore, various flavonoid-based
compounds, including quercetin, have been found to inhibit
eukaryotic e5NT (Braganhol et al., 2007). However, the molec-
ular basis for e5NT inhibition by these compounds is unknown.
Crystal structures of eukaryotic e5NT are therefore highly sought
after to provide a suitable template for structure-based drug
design.
To further our understanding of the eukaryotic e5NT family
we have determined crystal structures of human e5NT in
complex with various ligands in both open and closed conforma-
tions. The human e5NT structures described here not only
provide a foundation for understanding eukaryotic e5NT dimer-
ization, domain movement, substrate specificity and catalysis,
but also offer a suitable template for structure-based drug
design. With the elucidation of the human e5NT structure, we
are one step closer to our goal of understanding the molecular
principles behind signal conversion and inactivation in purinergic
signaling.
RESULTS
Overall Structure of Human e5NT
Using functionally active protein refolded frombacterial inclusion
bodies, crystal structures of human e5NT in both open and
closed conformations have been determined to 1.55–2.00 A˚
resolution (Tables 1 and 2). The crystal structures are from three
distinct crystal forms and are in complex with adenosine,
AMPCP, and two additional e5NT inhibitor compounds.2162 Structure 20, 2161–2173, December 5, 2012 ª2012 Elsevier LtdThe e5NT crystal structures reveal dimeric structures, which
is in agreement with observations from previous studies,
demonstrating that the enzyme exists and functions as a nonco-
valent dimer (Martı´nez-Martı´nez et al., 2000). The two distinct
open conformations of human e5NT have relatively compact
structures with dimensions 110.6 3 78.5 3 55.2 A˚ (crystal
form I) and 127.0 3 70.5 3 57.0 A˚ (crystal form II), whereas
the closed conformation has an elongated dimer structure
with dimensions of 141.1 3 57.9 3 58.5 A˚ (crystal form III)
(Figure 1).
Each subunit of the e5NT dimer consists of two structural
domains: the N-terminal domain (residues 27–317) and the
C-terminal domain (residues 337–549), which closely resemble
the structural domains of the monomeric bacterial 5NT enzymes
(Figure 2). The larger N-terminal domain of e5NT contains the
metal ion binding site and has a four-layered a/b-b-b-a structure,
including two sandwiched mixed b sheets. The C-terminal
domain contains the substrate binding site and dimerization
interface, and has a four-layered structure of the composition
a/b-b-a-b. The two domains are linked by a single a helix (resi-
dues 318–336) comprising a small hinge region, which enables
the enzyme to undergo large domain movements and thereby
switch between the open and closed conformations (see below).
The active site, observed in the closed conformation, is located
at the interface between the N- and C-terminal domains and is
formed from residues of both domains.
Dimerization Interface
In contrast to the monomeric bacterial 5NT enzymes (and
C. albicans 5NT), eukaryotic e5NT exists and functions as a non-
covalent homodimer. The dimerization interface involves only
the C-terminal domains that are related by a 2-fold axis of
symmetry such that both C termini are surface exposed and
located on the same side of the dimer. A surface area ranging
from 977 A˚2 (crystal form II) to 1609 A˚2 (crystal form I) is buried
upon dimer formation via a network of hydrophobic interactions
and hydrogen bonds (Figure 3; Table S1 available online).
Although the dimer interface is strongly influenced by interchain
domain movements (see below), a hydrogen bond between
P482 and V542 is present in all crystal forms as is a characteristic
cavity of water molecules surrounding residues D366 and E543
(Figure 3).
Extensive e5NT Domain Movements
The crystal structures reveal an extensive active site closure
movement involving the N- and C-terminal domains. This rota-
tional movement of up to 114 is the largest domain rotation so
far observed for the eukaryotic e5NT and bacterial 5NT enzymes
(Figure 4; Table S2). It is accompanied by interchain domain
movements of the two C-terminal domains at the dimer inter-
face. This interchain rotational movement of up to 13 between
the two open conformations strongly influences the molecular
interactions and buried surface area of the dimer interface (Fig-
ure 4; Table S2).
Binding Mode of the Product Adenosine
In both open conformations (crystal forms I and II), well-defined
electron density for adenosine is visible within the substrate
binding site of the C-terminal domain (Figures 5 and S1).All rights reserved
Table 1. Crystal Data and Refinement Statistics
Open-I Open-II PSB11552 Baicalin Closed
Crystallization and Data Collection
Reservoir 1.0 M LiCl, 0.1 M
HEPES pH 7.0
1.8 M MgSO4, 0.1 M
Tris-HCl pH 8.5
8% PEG 6,000, 0.1 M
Tris-HCl pH 7.8
6% PEG 6,000, 0.1 M
Tris-HCl pH 8.0
5% PEG 6,000, 0.1 M
citric acid pH 5.0
Drop additives 1 mM AMPCP 1 mM AMPCP 10 mM PSB11552,
1 mM ZnCl2
1 mM ZnCl2 1 mM AMPCP,
10 mM ZnCl2
Cryobuffer and soaking 3.0 M Na-malonate,
0.1 M Tris-HCl
pH 8.0
3.0 M Na-malonate,
0.1 M Tris-HCl
pH 8.0
20% glycerol, 0.2 M
Tris-HCl pH 8.0,
20% PEG 6,000,
10 mM PSB11552
20% glycerol, 0.2 M
Tris-HCl pH 8.0,
20% PEG 6,000,
11 mM baicalin
25% PEG200, 0.1 M
MES pH 5.5
Crystal form I II II II III
Protein constructa 1 1 2 2 3
Bound ligands Adenosine Adenosine PSB11552 Baicalin AMPCP
PDB ID 4H2F 4H2G 4H1Y 4H2B 4H2I
Space group P4332 P212121 P212121 P212121 C2221
Cell Dimensions (A˚)
a 167.6 67.1 67.5 67.2 53.2
b 167.6 131.0 131.9 131.2 94.9
c 167.6 66.0 66.3 66.3 234.3
Resolution (A˚) 41.89–1.85 29.34–1.55 19.75–1.58 19.82–1.67 24.65–2.00
Highest shell (A˚) 1.95–1.85 1.59–1.55 1.67–1.58 1.76–1.67 2.11–2.00
Rmerge (%)
b 10.0 (57.4) 4.8 (38.3) 7.4 (42.1) 5.9 (38.0) 8.5 (50.7)
Mean I/s (I)b 20.6 (4.1) 21.4 (3.7) 12.2 (2.9) 16.6 (3.2) 13.6 (3.8)
Completeness (%)b 100.0 (100.0) 99.4 (94.9) 99.7 (98.4) 99.9 (99.7) 99.9 (100.0)
Redundancyb 18.7 (10.6) 4.0 (3.2) 4.9 (4.7) 4.9 (4.6) 6.5 (6.5)
Monomers/asymmetric unit 1 1 1 1 1
Refinement
Resolution (A˚) 41.92–1.85 29.18–1.55 19.75–1.58 19.82–1.67 24.22–2.00
Number of reflections 67,420 84,411 79,925 66,541 39,304
Rwork/Rfree (%) 15.7/17.9 12.8/18.1 17.0/19.6 15.0/18.1 16.9/21.5
Number of atoms
Protein 4,132 4,159 4,256 4,222 4,095
Ligands 21 21 41 34 29
Metal ions 1 2 2 2 2
Water 507 783 642 411 393
B factors (A˚2)
Protein 15 14 16 19 17
Ligands 23 20 38 46 32
Metal ions 19 12 9 11 22
Water 42 48 29 27 45
Rmsd
Bond length (A˚), Z score 0.023, 1.158 0.022, 1.134 0.020, 1.006 0.026, 1.041 0.019, 0.947
Bond angle (), Z score 2.38, 1.104 2.00, 0.955 2.01, 0.961 2.06, 0.986 2.02, 0.921
Ramachandran Statistics
Favored (%) 96.4 97.3 97.3 96.8 96.2
Allowed (%) 3.4 2.5 2.5 3.0 3.6
Disallowed (%)c 0.2 0.2 0.2 0.2 0.2
aDetails for the protein constructs are given in Table 2.
bValues in parentheses are for the highest-resolution shell.
cResidue Q88 is in the disallowed region of the Ramachandran plot. Its conformation is well defined in all electron density maps.
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Table 2. Human e5NT Protein Constructs Used in This Study
Construct N- or C-Terminal Purification Tags Surface Mutations
1 MAHHHHHHVGTGSNDDDDKSPDP-(W27ELT-e5NT-IKFS549) N53D, N311D, N333D, N403D, K478A, R480A
2 MAHHHHHHVGTGSNDDDDKSPDP-(W27ELT- e5NT-IKFS549) N53D, N311D, N333D, N403D, K145S, K147S, K478S
3 M-(W27ELT-e5NT-IKFS549)-LEHHHHHH N53D, N311D, N333D, N403D
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Crystal Structure of Human Ecto-50-NucleotidaseBecause the crystals were obtained in the presence of AMPCP,
the adenosine ligand is either derived from adenosine impuri-
ties of the AMPCP substance or it is formed after hydrolytic
removal of the PCP (a,b-methylene diphosphate) moiety by
the enzyme in solution. The nucleobase is sandwiched between
the side chains of two phenylalanine residues (F417 and F500),
forming a clamp for the adenosine base via strong hydro-
phobic p-stacking interactions. Hydrogen bonds between the
ribose moiety and the side chains of R354, R395, and
D506 help to position the nucleoside. All other molecular inter-
actions between adenosine and the substrate binding site
involve hydrogen bonds mediated through water molecules.
In the open conformations the adenosine product is bound
more than 17 A˚ away from the di-metal catalytic center. The
observed binding mode of the adenosine product might be
influenced by one crystal contact to D270 of a neighboring
monomer (Figure S1). However, this binding mode is very
similar to that observed for E. coli 5NT (Kno¨fel and Stra¨ter,
2001b).
Crystal Structure of Human e5NT in Complex
with AMPCP
To obtain a structure of the closed state, the protein was crystal-
lized in the presence of Zn2+ and the nonhydrolyzable ADP
analog, AMPCP. In the closed conformation (crystal form III),
well-defined electron density for AMPCP and two metal ions is
visible within the active site. The active site is located at the inter-Figure 1. Overview of the Human e5NT Crystal Structure
E5NT in an open conformation (crystal form I), and a closed conformation (crystal f
blue and green, respectively. The N- and C-terminal domains of the adjacent su
AMPCP in the open and closed forms respectively) are shown as red sticks while
anchors and the cell membrane are also shown. A movie visualizing the conform
2164 Structure 20, 2161–2173, December 5, 2012 ª2012 Elsevier Ltdface between the N- and C-terminal domains and comprises
both the metal ion and substrate binding sites. The active site
in its closed state is largely solvent inaccessible.
The adenosine moiety of AMPCP is stabilized in a manner
similar to that observed for the adenosine binding mode
described above. Additional interactions with the PCP group
include hydrogen bonds between the a-phosphonate group
and the side chains of N245, R354, and R395, and between
the b-phosphonate group and the side chains of N117, H118,
and R395. H118 is strongly conserved in this superfamily of
metallophosphatases and usually bound to an aspartate
(D121 in e5NT) to form a catalytic Asp-His-dyad for transition
state stabilization (Kno¨fel and Stra¨ter, 2001b). Furthermore the
b-phosphonate group is coordinated to both metal ions such
that the nucleophilic water molecule observed in the E. coli
5NT AMPCP (PDB code: 1HPU) binding mode is displaced.
The two metal ions are coordinated in distorted trigonal-bipyra-
midal geometries and are bridged monodentately by the side
chain of D85, and bidentately by the b-phosphonate group of
AMPCP (Figure 6).
A large pocket (210 A˚3) with bound water molecules is
formed adjacent to the C2 atom of the adenine ring (Figure 6B).
It has a predominantly hydrophobic base formed by F421, P498,
L389, and L415 and polar- (N390, N499) or even-charged (D524)
sides. This pocket is formed entirely from the C-terminal domain
and it might be explored to design inhibitors extending from the
adenine clamp into the cavity.orm III). The N- andC-terminal domains of one subunit of the dimer are shown in
bunit are shown in orange and yellow, respectively. Ligands (adenosine and
the metal ions are shown as gray spheres. Schematic representations of GPI
ational switch is provided as Supplemental Information.
All rights reserved
Figure 2. Protein Fold of Human e5NT
(A) E5NT monomer in an open conformation (crystal form I). The N- and C-terminal domains are shown in blue and green respectively, whereas the connecting
a helix is shown in yellow. The adenosine ligand is shown as red sticks. The metal ion is shown as a yellow sphere. Disulfide bonds (yellow sticks) and
N-glycosylation sites (purple sticks) are highlighted, and the N and C termini (NT and CT, respectively), b strands (1–26), and a helices (A–P) are labeled.
(B) Superposition of individual domains of E. coli 5NT (PDB code: 1USH, red) onto the e5NT monomer shown in (A).
(C) Topology diagram of human e5NT. Triangles represent b strands and circles a helices. The topology of E. coli 5NT (Kno¨fel and Stra¨ter, 1999) is underlaid in
gray, highlighting the conservation, deletion, and addition of structural elements.
(D) Structure-based sequence alignment between human e5NT and the bacterial 5NT enzymes from E. coli and T. thermophiluswith known structure. Conserved
residues are underlaid in black and gray, disulfide bonds in yellow, N-glycosylation sites in purple, and the human e5NTGPI-anchor attachment site in red. N- and
C-terminal residues not present in the mature enzyme are shown in gray. Furthermore, secondary structure and catalytic residues (marked with an asterisk) of
human e5NT are shown above the sequence alignment.
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Crystal Structure of Human Ecto-50-NucleotidaseComparison of the Human e5NT and Bacterial 5NT
Structures
Structural comparisons between the human e5NT and bacterial
5NT enzymes were carried out in order to gain further insight into
the molecular basis for catalysis and substrate specificity, and
also for the molecular basis of inhibition. Of the known bacterial
5NT structures, Thermus thermophilus 5NT (PDB code: 2Z1A;
37% amino acid identity) most closely resembles human e5NT,
and this is in agreement with the higher sequence identity (TableStructure 20, 2161–21S3). Other closely related bacterial 5NT enzymes with known
structure include: Haemophilus influenzae NadN (PDB code:
3ZTV; 28% identity), and E. coli 5NT (PDB code: 1USH; 25%
identity).
Superposition of the individual domains of human e5NT and
the bacterial 5NT enzymes described above reveal similar
domain structures, with root mean-square deviation (rmsd)
values below 2.0 A˚ of aligned residues for both the N- and
C-terminal domains (Table S4). Differences in domain structure73, December 5, 2012 ª2012 Elsevier Ltd All rights reserved 2165
Figure 3. Dimerization Interface of Human e5NT
(A) Buried surface area of the dimer interface in the closed conformation of e5NT (crystal form III). The figure is colored as described in Figure 1, and the boxed
area represents the view of the dimerization interface in (B). Secondary structure elements involved in dimerization are labeled.
(B) Residues at the e5NT dimerization interface. Residues from one subunit of the dimer are shown as yellow sticks, while residues from the adjacent subunit are
shown as green sticks. Water molecules near residues D366 and E543 are shown as red spheres, whereas all other water molecules are omitted for clarity. The
view is looking directly onto the dimerization interface as indicated by the box in (A). See Table S1 for a list of interactions involved in dimer formation.
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structure elements are highly conserved.
Catalytic residues of both the substrate and metal ion binding
sites are highly conserved among the human e5NT and bacte-
rial 5NT enzymes. A notable exception is N245 of the human
e5NT metal ion binding site, which is replaced by either a histi-
dine or glutamine in the bacterial 5NT enzymes. In contrast to
the histidine and glutamine ligands, the shorter side chain of
human e5NT N245 is not able to coordinate the metal ion.Figure 4. Domain Movements of Human e5NT
(A) The e5NT active site closure movement. Monomers from the three crystal forms
gray.The threecrystal formsdiffer in relativedomainorientationsofup to114. The ro
and green) and the closed conformation (blue) show a similar orientation (green
ing the transition between the two open conformations is markedly different (gray d
(B) Dynamic nature of the e5NT dimerization interface. Dimers from the three crys
shown in gray. For clarity only the C-terminal domains of the human e5NT dimer
domain orientations of up to 13. The rotation axis describing the transition betwee
have a similar orientation and have been omitted for clarity. With respect to themo
between the two open conformations. Table S2 lists the rotation angles and rmsd
2166 Structure 20, 2161–2173, December 5, 2012 ª2012 Elsevier LtdN245 instead binds a water molecule that in turn coordinates
M1. E. coli 5NT N431, which coordinates N1 of the adenine
base, is replaced by G419 in human e5NT and consequently
a water molecule is instead hydrogen bonded to N1. Escheri-
chia coli 5NT R375 that binds the a-phosphate, is replaced
by S350 in human e5NT that is not interacting with the
substrate.
Superposition of human e5NT and bacterial 5NT structures
that have AMPCP bound at the active site reveal differentof human e5NT were superimposed based on the C-terminal domain shown in
tationaxesdescribing the transitionbetween the twoopenconformations (yellow
and yellow dashed lines), whereas the orientation of the rotation axis describ-
ashed line). The mechanical hinge regions (residues 332–336) are shown in red.
tal forms of human e5NT were superimposed based on the C-terminal domain
(colored as in A) are shown. The three crystal forms differ in relative interchain
n the two open conformations is shown (red dashed line). All other rotation axes
vement at the dimerization interface the closed conformation is an intermediate
values for the comparison of the domain orientations of the e5NT structures.
All rights reserved
Figure 5. The Adenosine Binding Mode
Stereo-view of adenosine bound to the substrate
binding site of an open conformation (crystal form
II). Water molecules in a cavity next to the adenine
binding site are shown, while all other waters are
omitted for clarity. The adenosine omit-electron
density map (Fo-Fc omit map, contoured at 3.0 s)
is depicted in blue.
See also Figure S1.
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Crystal Structure of Human Ecto-50-Nucleotidaseorientations of the substrate and metal ion binding sites, which
form the active site (Figure 7). Whereas the e5NT AMPCP
bound structure represents an inhibitory binding mode, the
E. coli 5NT AMPCP bound structure represents a plausible
substrate binding mode and has formed the basis for the
proposed bacterial 5NT catalytic mechanism (Kno¨fel and
Stra¨ter, 2001b). The superposition of the N-terminal domains
of E. coli 5NT and human e5NT shows that the binding modes
of the terminal phosphonate groups to the di-metal center
differ (Figure 7A). In the E. coli structure, the terminal phospho-
nate group is monodentately coordinated to the M2 metal ion
(occupying metal ion binding site 2) such that the leaving group
is positioned in an almost perfect inline arrangement to the
water nucleophile coordinated to the M1 metal ion (occupying
metal ion binding site 1) (Figure 6C). In the human enzyme, the
terminal phosphonate group bidentately bridges the two metal
ions, thus replacing the water nucleophile at M2. These differ-
ences in the AMPCP binding modes are caused by the
different domain orientations. If we superimpose the two
domains of e5NT individually generating a model of human
e5NT in which the domains are oriented as in the E. coli struc-
ture (Figure 7B), it becomes apparent that AMPCP adopts
almost the same conformation in the two structures, and there
are hardly any differences between the structures of the indi-
vidual domains and interactions with AMPCP. Thus, if the
C-terminal domain of the human enzyme could adopt the
same domain orientation of E. coli 5NT as shown in Figure 7B,
ADP could likely adopt a productive binding mode and be
hydrolyzed.
The domain orientations in the productive E. coli binding
mode and in the inhibitory AMPCP binding mode of the human
enzyme differ in a rotation of 26. There are no obvious differ-
ences in the active site structures (other than the domain orien-
tations) that are likely to cause the AMP substrate selectivity
in eukaryotic e5NT. In fact, a Q254N, R375S, N431G, triple
mutant of E. coli 5NT (‘‘humanizing’’ the active site of the
E. coli enzyme) shows no enhanced selectivity toward AMP
(data not shown). Thus, we assume that structural control of
the domain orientations ensures that only AMP can be hydro-
lyzed by the human enzyme whereas in the E. coli enzyme
domain orientations can be adopted that allow for the hydrolysis
of AMP, ADP, and ATP.Structure 20, 2161–2173, December 5, 2012 ªCocrystal Structures with
Nucleotide-Derived and Flavonoid-
Based Inhibitor Compounds
To support structure-based inhibitor
design, we determined the binding
modes of two synthetic e5NT inhibitorsto the open conformation (crystal form II). Due to crystal pack-
ing, crystal form I is not suitable for inhibitor binding studies
because the nucleotide binding site is close to crystal contacts.
Also, all attempts to obtain complex structures of e5NT in
the closed form (crystal form III) with compounds other than
AMPCP have so far failed, as these crystals form only in the
presence of the ADP analog which cannot be replaced by other
compounds. PSB11552 (2,20-(2-(2-((2S,3S,4R,5R)-5-(2,4-dioxo-
3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-
carboxamido)ethylamino)-2-oxoethylazanediyl) diacetic acid) is
a peptidonucleoside, which was designed as a nucleotide-
mimetic ecto-nucleotidase inhibitor (Brunschweiger et al.,
2008). It was found to inhibit rat e5NT at lowmicromolar concen-
trations using a capillary-electrophoresis-based assay (Iqbal
et al., 2008).
Its nucleobase is tightly sandwiched via p-stacking interac-
tions between the side chains of F417 and F500 (adenine clamp).
The uracil base and ribose moieties of the inhibitor form
hydrogen bonds with the side chains of N390, R395, and
D506, whereas the tail of the PSB11552 inhibitor is less well
ordered and sticks into the solvent, where the keto and carbox-
ylate groups are solvent exposed (Figure 8).
Baicalin (5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-
b-D-glucuronide) is a flavonoid similar to quercetin, which has
been found to inhibit e5NT with low micromolar affinity as
a noncompetitive or mixed inhibitor (Kavutcu and Melzig,
1999; Braganhol et al., 2007). We tested the binding of baicalin
to e5NT after soaking crystal form II in 11 mM of the compound
and found unambiguous density at the substrate binding site
(Figure 8). Baicalin appears to be a relatively weak inhibitor,
as we observed no significant inhibition at 128 mM baicalin.
Higher concentrations could not be tested due to the limited
solubility of the compound under assay conditions (baicalin is
highly soluble in the polyethylene glycol-containing crystalliza-
tion buffer). The planar chromene ring is sandwiched between
the side chains of F417 and F500 and the glucuronic acid
moiety interacts with the side chains of D506, R354, and
R395, thus replacing interactions of the ribose and diphospho-
nate groups of AMPCP. The phenyl ring extends toward
the pocket next to the adenine binding site, but the weak
density indicates flexibility resulting from a suboptimal fit to
the pocket.2012 Elsevier Ltd All rights reserved 2167
Figure 6. The AMPCP Inhibitory Binding
Mode
(A) Stereo-view of AMPCP bound at the e5NT
active site of the closed conformation (crystal form
III). The two zinc ions are shown as gray spheres.
The protein residues of the C-terminal domain
forming the substrate binding site are shown in
green whereas the amino acids of the N-terminal
domain are depicted in blue. Water molecules,
unless coordinating metal ions, are omitted for
clarity. The AMPCP omit-electron density map
(Fo-Fc omit map, contoured at 3.0 s) is shown in
blue.
(B) Pocket formed by the C-terminal domain next
to the adenine binding site. The e5NT molecular
surface around the pocket and the AMPCP ligand
is shown half transparent.
(C) Comparison of the binding modes of the
terminal phosphonate groups of AMPCP to the
dimetal cluster of human e5NT (bright colors) and
E. coli 5NT (gray and dim colors).
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Implications of the Domain Rotation and Dimer
Formation
The human e5NT structures presented here display domain
rotations of up to 114 and this is the largest domain movement
so far observed for the eukaryotic e5NT and bacterial 5NT
enzymes. This extensive active site closure movement involving
the N- and C-terminal domains of the e5NT monomer is thought
to be necessary for human e5NT catalysis, permitting substrate
binding and product release (Schultz-Heienbrok et al., 2005;
Stra¨ter, 2006). In addition, it appears that the active site closure
movementmay control human e5NT substrate specificity toward
AMP, and thereby inhibition by ADP and ATP, as discussed
below.
Determination of the e5NT dimer structure resulted in two
surprising findings: (1) the dimer interface is formed via the
C-terminal domains, and (2) it shows a significant plasticity asso-
ciated with the intrachain movements of the N- and C-terminal
domains. For the monomeric E. coli 5NT, the 96 domain
motion (Kno¨fel and Stra¨ter, 2001a) can be described either
such that the C-terminal domain rotates around its center
(leaving the N-terminal domain fixed) or such that the N-terminal
domain slides along the surface of the C-terminal domain.
Although both descriptions of the relative domain reorientations
are fully equivalent considering the protein alone, a rotational
movement of the C-terminal domain appears to be a more real-
istic view for the situation in solution, because the motion of the
C-terminal domain around its center would require much less2168 Structure 20, 2161–2173, December 5, 2012 ª2012 Elsevier Ltd All rights reserveddisplacement of water molecules result-
ing in less friction compared to the move-
ment of the large N-terminal domain. In
contrast to the bacterial 5NT enzymes,
human e5NT exists as a noncovalent ho-
modimer (Martı´nez-Martı´nez et al., 2000).
Thus, one domain is fixed to the other
subunit for dimer formation and theC-terminal domain is attached to the cell membrane via a GPI
anchor. To avoid the frictional movement of the N-terminal
domain, we had anticipated that the large N-terminal domains
would form the dimer interface and the long flexible GPI-anchor
would accommodate the large rotational movements of the
C-terminal domains. However, the human e5NT crystal struc-
tures presented here reveal that the e5NT dimerization interface
is formed by the twoC-terminal domains that are anchored to the
cell membrane. The two subunits of the dimer are related by a
2-fold axis of symmetry such that both C termini are surface
exposed and located on the same side of the human e5NT dimer.
Based on this observation, it is almost certain that the human
e5NT dimer is oriented relative to the cell membrane such that
theGPI-anchored C termini face the cell membrane. In this orien-
tation, theN-terminal domainswould extend into the extracellular
space where they would be free to rotate about the C-terminal
domains to switch between the open and closed conformations
(Figure 1; Movie S1). As a consequence, a large body of water
must be displaced during this extensive closure motion.
The second surprising finding of the e5NT dimer structure is
that the switch between the open and closed forms of the en-
zyme is accompaniedby a large rearrangement of the dimer inter-
face. A 13 rigid body rotation of the two C-terminal domains at
the dimer interface, accompanied by a change of the buried
surface by 630 A˚2, is observed between the two open forms.
In all three crystal forms the asymmetric unit contains one mono-
mer, such that the dimerization interface and interdomain orienta-
tionof thesubunitsarealwaysperfectlysymmetric. Thesefindings
might indicate that the two subunits move in a correlated fashion
Figure 7. Structural Comparison of the
Human e5NT and Bacterial 5NT Structures
(A) Stereo-view of the human e5NT AMPCP bound
structure superimposed onto the AMPCP bound
structure of E. coli 5NT (PDB code: 1HPU) based
on the N-terminal domains.
(B) Superposition of the individual domains of the
human e5NT AMPCP bound structure onto the
E. coli 5NT structure (i.e., a model is generated in
which the domains of the human enzyme are
oriented as in the E. coli structure). AMPCP is
superimposed with the C-terminal domain.
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Crystal Structure of Human Ecto-50-Nucleotidase(i.e., the two subunits always adopt a similar closure angle).
Because the N-terminal domains do not interact with each other
andare free tomovealong thedomain interface, sucha concerted
closure motion might be enforced by the coupling of the domain
movement to the structural changes of the dimer interface that
maintains a symmetric C2 interaction symmetry.
E5NT Substrate Specificity, Inhibition,
and Structure-Based Inhibitor Development
Crystal structures of human e5NT in complex with adenosine
and AMPCP reveal themolecular interactions involved in eukary-
otic e5NT inhibition and further our understanding toward
eukaryotic e5NT substrate specificity. Feed-forward inhibition
of mammalian e5NT by ATP and ADP prevents the formation
of antiinflammatory adenosine via the release of extracellular
ATP and may play an important role in the control of the concen-
tration and physiological activity of the extracellular adenine
nucleotides (Yegutkin, 2008). The human e5NT adenosine and
AMPCP binding modes reveal that positioning of the ligand
within the substrate binding site is largely dependent upon the
hydrophobic p-stacking interactions with the side chains of
F417 and F500. Almost all other molecular interactions between
the nucleobase and e5NT involve hydrogen bonds mediated
through water molecules, thereby resulting in the low base spec-
ificity observed for the e5NT enzymes.
In this study, we observed an inhibitory AMPCP bindingmode,
whereby the b-phosphonate is coordinated bidentately by theStructure 20, 2161–2173, December 5, 2012 ªtwo catalytic metal ions. This is in
contrast to the AMPCP binding mode
observed for E. coli 5NT, where the
b-phosphonate is coordinated by the
M2 metal ion. This structure represents
a productive ADP binding mode and has
formed the basis for the proposed cata-
lytic mechanism (Kno¨fel and Stra¨ter,
2001b). ADP probably adopts a similar
inhibitory binding mode as AMPCP in
the e5NT active site replacing the nucleo-
philic water molecule such that hydrolysis
cannot occur. This explains why nucleo-
tide diphosphates are not readily hydro-
lyzed by human e5NT.
As outlined in the results section,
a comparison of the domain orientations
of the AMPCP complex structures ofE. coli 5NT and human e5NT suggests that structural control
of the domain motion determines the substrate selectivity of
e5NT toward monophosphate nucleotides and the inhibitory
properties of di- and triphosphate nucleotides. Although it is
not immediately obvious from the results of this study that inter-
actions might prevent the human e5NT enzyme from forming
a closed structure similar to that observed for E. coli 5NT so as
to permit the hydrolysis of di- or triphosphate nucleotides,
a comparison of the active site structures of human e5NT and
E. coli 5NT suggests no other factors that might directly control
the substrate specificity of the eukaryotic enzymes. It has also
become apparent from this study that the intrachain domain
rotation must be taken into account for computational struc-
ture-based studies toward more potent e5NT inhibitors,
as there may be significant flexibility of the domain orientations
allowing different inhibitors to bind to the closed state.
We have determined structures of both open and closed forms
of human e5NT, which can be utilized for the computational
design of inhibitors binding to the open and closed states.
Crystal form II is suitable for studying the binding mode of
compounds to the open enzyme. In this study, we determined
the binding mode of the nucleotide-derived inhibitor compound
PSB11552 and of the flavonoid-based inhibitor compound
baicalin to provide additional insight for the development of
selective human e5NT inhibitors. Both inhibitor compounds
show strong molecular interactions with the substrate binding
site but also extend out of the substrate binding pocket. For2012 Elsevier Ltd All rights reserved 2169
Figure 8. Binding Modes of PSB11552 and
Baicalin to e5NT
(A and B) Views of PSB11552 (A) and baicalin (B)
bound within the substrate binding site (crystal
form II). Water molecules are omitted for clarity.
The inhibitor omit-electron density maps (Fo-Fc
omit maps, contoured at 2.0 s) are shown in blue.
(C and D) Schematic representations of the inter-
actions of PSB1152 (C) and baicalin (D) with the
substrate binding site. A legend describing the
color coding scheme can be found as Scheme S1.
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of the inhibition mode of this compound as the carboxylate
tail is positioned such that it could potentially interact with the
metal ions in the closed e5NT conformation. Nevertheless, these
structures provide insight into human e5NT inhibition by novel
nucleotide-derived and flavonoid-based inhibitor compounds.
In addition to supporting e5NT inhibitor development, our data
will also facilitate the structure-guided design of prodrugs for
adenosine receptors that are converted to active receptor
agonists via e5NT (El-Tayeb et al., 2009; Flo¨gel et al., 2012).
Unfortunately, crystal form III (closed conformation) appears
not to be suitable for experimentally studying the binding mode
of inhibitors, other than ADP-derived compounds, to the closed
form. The closed form provides a larger binding pocket than the
nucleoside binding site alone permitting further interactions with
the His-Asp dyad and the di-metal center. Inhibitors that bind to
both domains need to fix the enzyme in the closed conformation
for binding, resulting in a loss of entropy for the domain flexibility
(1–3 degrees of freedom). In addition to interactions with the
N-terminal domain, the pocket adjacent to the adenine binding
site might be explored for additional interactions. These inhibi-
tors need not to compensate the entropy penalty associated
with the conformational freedom of the domain flexibility for tight
binding. Larger substituents at the C2 next to the phenyl ring of
baicalin may be introduced for a complementary fit to the hydro-
phobic base of the pocket as well as the polar or charged resi-
dues lining the pocket sides.
The present structures have been determined for protein
expressed in E. coli without the GPI signal sequence and they2170 Structure 20, 2161–2173, December 5, 2012 ª2012 Elsevier Ltd All rights reservedthus lack the membrane anchor and
resemble the soluble enzyme forms of
e5NT that are derived from a GPI-
anchored precursor by phospholipase
C cleavage (Zimmermann, 1992).
Because these soluble enzyme forms
have basically very similar kinetic and
inhibitory characteristics as the mem-
brane-bound ecto-enzymes, we assume
that our structural studies on the catalytic
mechanism, inhibition, and domain
motion are relevant for the soluble as
well as membrane-bound e5NTs. The
structural model shown in Figure 1 indi-
cates that anchoring of the dimer formed
by the C-terminal domains via the flexible
GPI anchor is unlikely to strongly influ-ence the motion of the N-terminal domain and the active site
structure.
In conclusion, the structures presented here further our under-
standing of eukaryotic e5NT dimerization, domain movement,
substrate specificity, and catalysis. The results open the field
for further experimental studies probing the hypothesis that the
domain motion controls e5NT substrate specificity and inhibition
by mono-, di-, and triphosphate nucleotides. Furthermore,
results from this study provide the foundations for structure-
based development of potent and selective e5NT inhibitors
that could in the future offer pharmaceutical and biological tools
to study purinergic signaling and promising drugs to interfere
with these signaling pathways.
EXPERIMENTAL PROCEDURES
Expression, Purification, and Crystallization
Recombinant human e5NTwas overexpressed in E. coli in the form of inclusion
bodies and refolded using the method of rapid dilution protein refolding
(see below). All recombinant human e5NT proteins used in this study
encode the mature human e5NT protein sequence (residues 27–549) and
correspond to the previously described T376A variant (database entry
P21589/VAR_022091 of UniProtKB/Swiss-Prot). The signal sequence respon-
sible for anchoring the protein to the membrane via GPI-anchor has been
omitted for the bacterial expression system. N- or C-terminal purification
tags were added to assist purification. Four asparagine to aspartate mutations
were introduced in all constructs to increase protein solubility and refolding
yields (Table 2). Some constructs bear additional point mutations to enhance
crystallization properties.
Details of the procedures developed to produce active human e5NT from
bacterial inclusion bodies will be described elsewhere. Briefly, renatured
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Crystal Structure of Human Ecto-50-Nucleotidasehuman e5NT protein was purified from misfolded species using AMP-agarose
affinity chromatography followed by size exclusion chromatography. The
N- and C-terminal purification tags were not removed during protein purifica-
tion. The activity of the refolded enzyme has been characterized by amalachite
green assay (Zebisch and Stra¨ter, 2007) in the presence 0 to 20 mM AMP in
a buffer containing 50 mM Tris-HCl pH 7.5 and 100 mM NaCl. All measure-
ments were carried out at least in triplicate. Km and Amax were calculated
with a nonlinear Hill function v = Amax 3 [S]
n/(Km
n + [S]n). One unit (U) equals
1 mmol phosphate/min. A specific activity of 577.2 ± 2.6 U/mg was determined
which is higher than the specific activity of 130 U/mg determined for human
e5NT purified from a human colon adenocarcinoma cell line (Navarro et al.,
1998). The Km value of 6.6 ± 0.2 mM is comparable or lower than the values
described for e5NTs fromdifferent sources (Zimmermann, 1992). The Hill coef-
ficient was close to 1.0. Crystallization trials for human e5NT used freshly
prepared and filtered (0.22 mm) protein in 10 mM Tris-HCl pH 8.0 at a protein
concentration of 5.0 mg/ml. Vapor diffusion crystallization trials were carried
out at 19C. Equal amounts of protein solution and reservoir buffer (see Table
1) were mixed, and AMPCP, PSB11552, and/or ZnCl2 were added to give the
drop concentrations listed in Table 1. After crystals had formed (1–2 days),
the crystals were transferred to a soaking and/or cryo buffer, that contained
the components listed in Table 1. All crystals were flash frozen in liquid
nitrogen. AMPCP was obtained from Jena Bioscience (Germany) and baicalin
from Carbosynth (Compton, UK). The synthesis and detailed characterization
of PSB11552 will be published elsewhere.
X-Ray Data Collection, Structure Determination, and Refinement
X-ray data collection was carried out at 100 K using a wavelength of 0.91841 A˚
on either beamline 14.1 or 14.2 of the Berlin Synchrotron (BESSY, Berlin,
Germany) equipped with a Rayonix MX-225 CCD detector (Marresearch
GmbH, Norderstedt, Germany). The X-ray data sets were indexed, integrated,
scaled, and converted to structure factor amplitudes using iMosflm (Battye
et al., 2011) or XDS (Kabsch, 2010), and Scala of the CCP4 suite (Winn
et al., 2011). Crystallographic statistics are shown in Table 1.
Molecular replacement was carried out usingMolRep (Vagin and Teplyakov,
2010), and a poly-alanine structural model, generated from T. thermophilus
5NT (PDB code: 2Z1A), which shares 37% amino acid sequence identity to
human e5NT, was used as an initial search model. Molecular replacement
was achieved by searching first for the larger N-terminal domain (residues
28–331) and then the smaller C-terminal domain (residues 332–531) of the
search model. Model building was carried out using the automated model
building program ARP/wARP (Langer et al., 2008), and the model was
improved by iterative manual rebuilding with Coot (Emsley et al., 2010) and
refinement with Refmac5 (Murshudov et al., 2011). Two TLS groups corre-
sponding to the N- (residues 26–335) and the C-terminal domains (residues
336–549) of human e5NT were used. Model building and TLS refinement
was carried out until convergence of the R-factors using Refmac5, and were
then further refined using BUSTER-TNT (Bricogne, 1993; Roversi et al.,
2000). Structures were validated using the CCP4 program ProCheck (Laskow-
ski, 2003), and any outliers of the Ramachandran plot were manually checked.
Structures were then analyzed by MolProbity (Chen et al., 2010) and manually
checked in Coot (Emsley et al., 2010).
Structural Analysis
Dimensions of the human e5NT structures were calculated using MOLEMAN2
(Kleywegt and Bru¨nger, 1996), and domain interfaces were analyzed using
PISA (Krissinel, 2011) (http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html).
Structural superpositions were carried out using a secondary structure
matching algorithm with the program Superpose (Krissinel and Henrick,
2004). Structures were superposed by the respective Ca atoms, using
a centroid approach with default radius cutoff settings. Therefore, flexible
loops showing large structural deviations were excluded from the alignment
and rmsd calculations. Interdomain rotation angles for the comparison of
two structures were obtained as follows. First, the C-terminal domains of
a pair of structures were superimposed (program Superpose) followed by
the N-terminal domains (or adjacent C-terminal domains of the human e5NT
dimer). The rotation matrices for the second superposition step (describing
the differences in the domain orientations) were converted to a screw operator
consisting of a rotation axis, the rotation angle, and a translation along theStructure 20, 2161–21axis using program MATCON (William Bennett, personal communication).
Figures were generated using PyMOL (PyMOL Molecular Graphics System,
Schro¨dinger; http://www.pymol.org).
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